The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $27.17

Today's change-0.11 -0.40%
Updated October 23 4:00 PM EDT. Delayed by at least 15 minutes.
 

Arena Pharmaceuticals Inc

Nasdaq: ARNA
Last

(U.S.) $27.17

Today's change-0.11 -0.40%
Updated October 23 4:00 PM EDT. Delayed by at least 15 minutes.

Arena Pharmaceuticals Inc down (U.S.)$0.11

Arena Pharmaceuticals Inc closed lower Monday, dropping (U.S.)$0.11 or 0.40% to (U.S.)$27.17. Over the last five days, shares have gained 6.30% and are currently 3.93% off of the 52-week high. Shares have outperformed the S&P 500 by 53.26% during the last year.

Key company metrics

  • Open(U.S.) $27.30
  • Previous close(U.S.) $27.28
  • High(U.S.) $27.49
  • Low(U.S.) $26.84
  • Bid / Ask(U.S.) $26.90 / (U.S.) $30.60
  • YTD % change+91.34%
  • Volume346,449
  • Average volume (10-day)481,488
  • Average volume (1-month)501,690
  • Average volume (3-month)980,962
  • 52-week range(U.S.) $11.30 to (U.S.) $28.28
  • Beta1.43
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.59
Updated October 23 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue678519
Total other revenue--------
Total revenue678519
Gross profit437916
Total cost of revenue3363
Total operating expense28274729
Selling / general / administrative7879
Research & development18161217
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0--220
Other operating expenses, total--------
Operating income-21-2138-10
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-24-2238-12
Income after tax-24-2238-12
Income tax, total--------
Net income-23-2239-12
Total adjustments to net income--------
Net income before extra. items-23-2239-12
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-23-2239-12
Inc. avail. to common incl. extra. items-23-2239-12
Diluted net income-23-2239-12
Dilution adjustment----00
Diluted weighted average shares30242424
Diluted EPS excluding extraordinary itemsvalue per share-0.77-0.901.59-0.51
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.77-0.902.48-0.50